Recent studies showed that nearly 15–20% PCa patients presented a loss of function of PTEN and the rate may reach 40–60% when the disease progress into the CRPC or metastatic stage (Yoshimoto et al., 2012; Leinonen et al., 2013; Jamaspishvili et al., 2018). This evidence concerns the gene PTEN and posterior cortical atrophy.